MedicubeX LTD

In 2027, MedicubeX launches world's first 10-year CVD prediction algorithm that doesn't require a blood test to function unlike the existing FRAMINGHAM and Risk2 scores.

It'll be a software as a medical device that people can use independently to calculate their risk of getting CVD. It'll benefit the healthcare system, as high risk individuals can be identified before it's too late.

MedicubeX's story began in 2016, when co-founders Heikki Rautajoki and Vili Kostamo first met during a research project on non-invasive diabetes screening, funded by the Academy of Finland and coordinated by VTT Technical Research Centre of Finland.

United by a shared enthusiasm for this technology, the co-founders began their journey toward establishing MedicubeX. After three years of preparation, MedicubeX was officially founded in March 2020, with Vili Kostamo, M.D., taking the role of CEO. The team dedicated the next three years to product development.

Following a highly successful first clinical pilot in Helsinki in April 2023, MedicubeX experienced rapid adoption. We have since grown from a promising startup into an established international partner, with active operations across Germany, the Nordics, the Baltics, and the UK.

The focus remains on driving fast international growth and continuing to innovate at the forefront of preventative healthcare technology.

Currently, the eHealth Stations™ are used for the following use cases

• CVD screening programs
• CVD prevention
• A&E triage
• Pre-operation assessment
• Primary care
• Occupational healthcare
• Non-urgent care: Pre-appointment measurements, follow-up
• Research data collection